DEADLINE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead…
SAN DIEGO, Jan 28, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock on the open market, or pursuant to Registration Statements…